Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BioNTech : UBS Adjusts Price Target on BioNTech to $300 From $111, Maintains Neutral Rating

08/27/2021 | 09:14am EDT


© MT Newswires 2021
All news about BIONTECH SE
10/25European ADRs Move Lower in Monday Trading
MT
10/25Moderna Shares Higher After Interim Data for Covid-19 Vaccine in Children
DJ
10/25UNIVERSITY OF BIRMINGHAM : A third of leukaemia patients do not generate any antibody resp..
AQ
10/22Health Care Up On Defensive Bias -- Health Care Roundup
DJ
10/22MODERNA : COVID SCIENCE-COVID-19 vaccines not linked to pregnancy loss; mixing vaccines ma..
RE
10/22Walmart, Walgreens U.S. stores roll out Moderna, J&J COVID-19 booster shots
RE
10/22PFIZER : FDA Panel to Vote on Pfizer COVID-19 Shots for Kids; Data Shows Vaccine 90.7% Eff..
MT
10/22European ADRs Move Higher in Friday Trading
MT
10/22PFIZER : Norway Stops Second Dose COVID-19 Vaccine Inoculations For Minors
MT
10/22PFIZER : BioNTech COVID-19 Vaccine Shows Nearly 91% Efficacy in Kids
MT
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 16 703 M 19 397 M 19 397 M
Net income 2021 8 797 M 10 215 M 10 215 M
Net cash 2021 8 661 M 10 058 M 10 058 M
P/E ratio 2021 7,23x
Yield 2021 -
Capitalization 61 368 M 71 229 M 71 265 M
EV / Sales 2021 3,16x
EV / Sales 2022 2,54x
Nbr of Employees 2 500
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Last Close Price 254,09 €
Average target price 254,59 €
Spread / Average Target 0,20%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE261.78%71 229
GILEAD SCIENCES, INC.16.15%84 845
WUXI APPTEC CO., LTD.24.08%64 399
REGENERON PHARMACEUTICALS19.27%59 906
VERTEX PHARMACEUTICALS-21.73%47 992
BEIGENE, LTD.49.95%36 160